Rocket Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Rocket Pharmaceuticals, Inc. (RCKT) had Additional Paid in Capital, Common Stock of $316.09 million as of 2017-12-31, per its 10-K filed 2018-03-07.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2018-03-07
- 2017-12-31: Additional Paid in Capital, Common Stock $316.09M.
- 2017-09-30: Additional Paid in Capital, Common Stock $314.33M.
- 2017-06-30: Additional Paid in Capital, Common Stock $313.44M.
- 2017-03-31: Additional Paid in Capital, Common Stock $312.61M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2017-12-31 | $316.09M 10-K · filed 2018-03-07 | |
| 2017-09-30 | $314.33M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $313.44M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $312.61M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $312.03M 10-K · filed 2018-03-07 | $311.83M 10-K · filed 2017-03-16 |
| 2016-09-30 | $310.69M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $309.93M 10-Q · filed 2016-08-10 | |
| 2016-03-31 | $305.07M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $304.58M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $304.06M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $163.45M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $163.29M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $76.47M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |